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ABSTRACT:VEGF inhibitors, including receptor tyrosinekinase inhibitors, areusedas adjunct therapies in anumber
of cancer treatments. An emerging issue with these drugs is that most cause hypertension. To gain insight into the
physiological mechanisms involved, we evaluated their regional hemodynamic effects in conscious rats. Male
SpragueDawleyrats (350–450g)werechronically implantedwithpulsedDopplerflowprobes (renal andmesenteric
arteries, and the descending abdominal aorta) and catheters (jugular vein, peritoneal cavity, and distal abdominal
aorta). Regional hemodynamicsweremeasured over 4 d, before and after daily administration of cediranib (3 and 6
mg/kg, 3 and 6 mg/kg/h for 1 h, i.v.), sorafenib (10 and 20 mg/kg, 10 and 20 mg kg/h for 1 h, i.v.), pazopanib (30
and100mg/kg, i.p.), or vandetanib (12.5 and 25mg/kg, i.p.). All drugs evoked significant increases (P < 0.05; n = 7–8)
in mean arterial pressure, which were generally accompanied by significant mesenteric and hindquarters, but not
renal, vasoconstrictions. The hypertensive effects of cediranib were unaffected by losartan (10 mg/kg/h), bosentan
(20 mg/kg/h), or a combination of phentolamine and propranolol (each 1 mg/kg/h), suggesting a need for new
strategies toovercomethem.—Carter, J. J., Fretwell,L.V.,Woolard, J.Effectsof4multitargetedreceptor tyrosinekinase
inhibitors on regional hemodynamics in conscious, freelymoving rats. FASEB J. 31, 1193–1203 (2017).www.fasebj.org
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Vascular endothelialgrowth factor (VEGF) is an important
mediator of cell survival, proliferation, and angiogenesis
(1–4). As a consequence, VEGF and its receptors have be-
come amajor focus of cancer research over the last decade
(4). Inhibitors of VEGF activity, including monoclonal
antibodies and receptor tyrosine kinase inhibitors (RTKIs),
have been developed to interferewith tumor angiogenesis
andmany are in the clinic as adjunct therapies to improve
cancer prognosis (5–7).
Bevacizumab (Avastin; Genentech, San Francisco, CA,
USA), a humanized anti-VEGF antibody, is currently
used in the treatment of metastatic carcinoma of colon
or rectum, lung (non-small cell), and kidney (5). The
RTKIs sunitinib and sorafenib have been licensed for use
in advanced renal cell carcinoma and gastrointestinal
stromal tumors (8), while cediranib is undergoing pre-
clinical testing for ovarian cancer (9), and vandetanib is
being used to treat medullary thyroid cancer (10). These
inhibitors were designed to be less specific, multi-
targeted agents compared tomonoclonal antibodies, and
although these approacheswere expected to causeminimal
adverse effects, thisdoesnot appear tobe thecase (8, 11–13).
An emerging issue with anti-VEGF therapies is the
development of significant hypertension, leading to left
ventricular dysfunction andheart failure after longer-term
exposure over several months (11–13). Approximately 20
to 30% of patients treated with the monoclonal antibody
bevacizumab (5) and 15 to 60% of patients treated with
small-moleculemultitargetedRTKIsexperienced treatment-
associated hypertension (13–17). Moreover, the develop-
ment and/or escalation of preexisting hypertension in these
patients has been linked to multiple severe complications,
including venous or arterial thromboembolism, acute heart
failure, and intracerebral hemorrhage (18–20). Thus, an
elevation in blood pressure (BP) often leads to treatment
cessation or possible life-threatening adverse events (13).
Some attempts have beenmade to recapitulate these hy-
pertensive effects in small animalmodels inorder toprovide
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insight into the potential mechanisms involved (21–23). In
telemetered rats, it was demonstrated that 8 d of treatment
with theRTKI, sunitinib-inducedanapproximate30mmHg
rise in BP, which was associated with an elevation in circu-
lating endothelin-1 and creatinine levels (21). Furthermore,
functional studies in coronary microvessels isolated from
these treatedanimalsdemonstratedreducedresponsiveness
to bradykinin, angiotensin II, and sodium nitroprusside;
this loss of functionalitywas not seen in preparationswhere
sunitinib treatment was withdrawn 11 d before experi-
mentation (21). Additional animal studies have suggested
that sunitinib has no direct effects on cardiac structure and/
or function (22). More recently, the effects of sunitinib and 2
other RTKIs, cediranib and sorafenib, on BPwere evaluated
in rats instrumentedwith radiotelemetric devices (23). All 3
VEGF signaling inhibitors showedhypertensive effects over
a range of doses, where a change in diastolic pressure was
used as an index of vasoconstriction. This ability to dem-
onstrate hypertensive effects in nonclinical in vivo models
suggests that further whole animal approaches should be
useful in unraveling the mechanisms underlying the de-
velopment of RTKI-induced clinical hypertension (23).
In thecontextofanimal studies, toourknowledge,noone
has shown whether the onset of hypertension after RTKI
administration is a cardiac or vascular event because all
previous approaches have been confined to the use of
implanted radiotelemetric devices, which are limited to
measurements of BP and heart rate (HR). The aims of the
current study were therefore to determine the following in
conscious rats: how early (0–4 d) hypertensive effects could
be observed with different RTKIs; whether these effects
were associated with vasoconstriction; and if this vasocon-
strictionwas regionally selective.Themodel chosenallowed
vascular conductance (VC) to be measured simultaneously
in 3 different vascular beds using Doppler flow probes su-
tured around the renal and mesenteric arteries and the
descending aorta (24–26). The 4 RTKIs chosen have been
previously shown to inhibit VEGF receptor 2 (VEGFR2)-
mediated reporter gene responses with a rank order of po-
tency of cediranib. pazopanib. sorafenib. vandetanib
(27). Because we were able to show regionally selective va-
soconstrictor effects that were particularly marked with
cediranib, we then investigated whether the cardiovascular
effects of cediranib could be prevented by antagonism of
angiotensin AT1 receptors (AT1Rs), endothelin-1 receptors,
or adrenoceptors.
MATERIALS AND METHODS
Animals and surgery
Adult male Sprague Dawley rats (Charles River Laboratories,
Wilmington, MA, USA) weighing 350 to 450 g were housed in
groups in a temperature-controlled (21–23°C) environment with
a 12-h light–dark cycle (lights on at 6:00 AM) and free access to
food (18% Protein Rodent Diet; Teklad Global, Bicester, United
Kingdom)andwater for at least 7d after arrival fromthe supplier
before any surgical intervention.
Surgery was performed in 2 stages under general anesthesia
(fentanyl and medetomidine, 300 mg/kg each, i.p., supplemented
as required), with reversal of anesthesia and postoperative
analgesia provided by atipamezole (1 mg/kg, s.c.) and
buprenorphine (0.02 mg/kg, s.c.). At the first surgical stage,
miniature pulsed Doppler flow probes were sutured around the
renal andmesenteric arteries and the descending abdominal aorta
tomonitor hemodynamics. The wires from the probes were taped
and sutured at the nape of the neck, and the animalswere returned
to theholding room.At the second surgical stage,which tookplace
at least 10 d after the surgery for probe implantation, and after a
satisfactory inspection from the Named Veterinary Surgeon,
catheters were implanted in the distal abdominal aorta via the
caudal artery (for arterial BPmonitoring and the derivation ofHR)
and in the right jugular vein (for drug administration). Three sep-
arate intravenous catheters were placed in the jugular vein to en-
able concurrent administration of different substances. In some
experiments, intraperitoneal catheters were inserted through the
abdominal wall. At this stage, the wires from the probes were sol-
dered into a miniature plug (Microtech, Boothwyn, PA, USA),
which was mounted onto a custom-designed harness worn by the
rat. The catheters emerged from the same point as the probe wires
andwere fed through a protective spring secured to the harness
and attached to a counterbalanced pivot system. The arterial
catheter was connected to a fluid-filled swivel for overnight in-
fusion of heparinized (15 U/ml) saline to maintain potency.
Experiments began 24 h after surgery for catheter implanta-
tion, with animals fully conscious and unrestrained in home
cages, and with free access to food and water. All procedures
were carried out with approval of the University of Nottingham
AnimalWelfareEthicalReviewBoardunderHomeOfficeProject
and Personal License Authority.
Cardiovascular recordings
Cardiovascular variables were recorded using a customized,
computer-based system (IdeeQ; Maastricht Instruments, Maas-
tricht, The Netherlands) that connected a transducer amplifier
(13-4615-50; Gould, Cleveland, OH, USA), a Doppler flowmeter
(Crystal Biotech, Holliston, MA, USA), and a VF-1 mainframe
(pulse repetition frequency 125 kHz) fitted with high-velocity
(HVPD-20) modules. Raw data were sampled by IdeeQ every
2 ms, averaged, and stored to disc every cardiac cycle. Changes
in renal VC (RVC), mesenteric VC (MVC), and hindquarter VC
(HVC), in the renal, mesenteric, and hindquarter vascular beds,
respectively, were calculated from the changes in mean arterial
pressure (MAP) and Doppler shift.
Experimental protocol
Experiments were run in 4 series; within each series was a con-
temporaneous control. Experiments were generally run with
treatment groups of 6 to 8 rats.
Series 1
Six groups of rats were used. On d 1 of the experiment, after a
period of baseline recording, rats were provided cediranib (3 or
6 mg/kg) or sorafenib (10 or 20 mg/kg) as an intravenous bolus
(0.1 ml provided over 5 s) followed by a 1-h intravenous infusion
(0.4 ml/h) at the same dose. Contemporaneous controls were pro-
vided vehicle (5% propylene glycol, 2% Tween 80 in sterile saline).
Recordingswere continued for a further 3 h after completion of the
intravenous infusion period. The same treatment regimen was fol-
lowed on d 2–4 after a period of baseline recording on each day.
Series 2
Sixgroups of animalswere used.Ratswere providedvandetanib
(12.5 or 25 mg/kg) or pazopanib (30 or 100 mg/kg) as an
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intraperitoneal bolus (0.1ml provided over 5 s). Solubility issues
withbothdrugspreventedutilizationof the intravenousprotocol
described above for cediranib and sorafenib. Instead, both drugs
were administered as single intraperitoneal bolus injections.
Contemporaneous controls were provided vehicle (5% pro-
pylene glycol, 2% Tween 80 in sterile saline, i.p.). Cardiovascular
recordings were continued for a further 4 h after administration
of the compounds. The same treatment regimen was repeated
on d 2–4 after a period of baseline recording on each day.
Series 3
Two groups of animals were used. Rats were provided the
AT1R antagonist losartan (10 mg/kg) as an intravenous bolus
(0.1 ml) followed by an intravenous infusion (10 mg/kg/h; 0.4
ml/h) over the entire monitoring period (28). Control animals
were provided vehicle (sterile saline). One hour after com-
mencement of the losartan or vehicle infusion, cediranib
(3 mg/kg, 3 mg/kg/h for 1 h) was provided to all animals.
Recordings were then continued for a further 3 h. The same
treatment regimen was repeated on d 2, with a final recording
being taken on d 3.
Series 4
Three groups of animals were used. Rats were provided the
endothelin-1 receptor antagonist bosentan (20 mg/kg; 20 mg/
kg/h infusion) (24) or a combination of thea- andb-adrenoceptor
antagonists phentolamine (1mg/kg; 1mg/kg/h infusion) and
propranolol (1 mg/kg; 0.5 mg/kg/h infusion) (29). Control
animals were provided the appropriate vehicle (5% propylene
glycol, 2% Tween 80 in sterile saline for bosentan, and sa-
line for phentolamine/propranolol). Vehicle, bosentan, or
phentolamine/propranolol infusions were continued for 5 h.
One hour after commencement of the drug or vehicle infusion,
cediranib (3 mg/kg, 3 mg/kg/h) was provided to all animals.
The same treatment regimen was repeated for each rat on d 2,
with a final baseline recording being taken on d 3. In the
bosentan-treatedgroup, endothelin (1mMasa0.1mlbolus in1%
bovine serum albumin/saline) was routinely administered at
the end of d 2 in all of our experiments to verify that the car-
diovascular effects had been significantly attenuated by the in-
fusion of bosentan (24).
Data analysis
Data were analyzed offline using IdeeQ software. For all
experiments, time-averaged data are shown as changes from
baseline [HR (beats/min);MAP (mmHg); VC (%)]. Statistical
comparisons between groups of animals were performed on
the integrated changes over specified time periods. Because
the data were not all normally distributed, a nonparametric,
repeated-measures analysis of variance (Friedman’s test)
(30) was used for within-group comparisons and Mann-
Whitney U test for between-group comparisons, as appro-
priate. Vascular conductances were calculated from the
MAP and Doppler shift (flow) data. A value of P, 0.05 was
considered significant. Each animal represented 1 experi-
mental unit.
RESULTS
Baseline cardiovascular variables before the administra-
tion of RTKIs and corresponding vehicles are shown in
Table 1.
TABLE 1. Baseline cardiovascular variables before administration of vehicle or RTKI
Series n
HR
(beats/
min)
MAP
(mmHg)
RDS
(kHz) RVC (U) MDS (kHz) MVC (U)
HDS
(kHz)
HVC
(U)
Series 1
Vehicle 1 7 362 6 16 106 6 4 8.8 6 0.5 83 6 4 9.8 6 1.4 93 6 14 5.4 6 0.4 51 6 3
Cediranib, low dose 8 359 6 8 106 6 4 8.6 6 0.9 82 6 8 9.3 6 0.6 90 6 8 6.0 6 0.5 57 6 4
Sorafenib, low dose 8 336 6 9 103 6 4 8.9 6 0.9 87 6 9 9.2 6 1.2 89 6 11 5.9 6 0.4 58 6 6
Vehicle 2 8 374 6 12 107 6 3 7.8 6 1.3 72 6 12 9.2 6 1.5 86 6 13 5.4 6 0.6 51 6 6
Cediranib, high dose 8 357 6 8 105 6 3 8.3 6 0.9 79 6 7 8.4 6 1.4 82 6 15 5.4 6 0.3 51 6 3
Sorafenib, high dose 7 347 6 4 102 6 5 9.3 6 0.9 90 6 5 7.5 6 1.0 74 6 9 5.6 6 0.4 55 6 5
Series 2
Vehicle 3 8 354 6 5 104 6 3 8.9 6 1.4 86 6 14 11.4 6 1.4 110 6 15 5.8 6 0.4 57 6 5
Vandetanib, low dose 8 368 6 4 98 6 2 8.8 6 0.9 90 6 9 10.0 6 1.3 102 6 12 6.2 6 0.5 64 6 7
Vandetanib, high dose 8 357 6 11 103 6 3 8.5 6 1.0 81 6 7 12.5 6 1.2 122 6 12 6.3 6 0.7 62 6 8
Vehicle 4 8 356 6 15 105 6 3 10.1 6 1.6 96 6 14 9.9 6 1.1 95 6 12 6.0 6 0.3 58 6 3
Pazopanib, low dose 8 360 6 6 97 6 1 9.2 6 0.5 95 6 5 11.4 6 1.2 118 6 13 5.5 6 0.4 57 6 4
Pazopanib, high dose 8 351 6 5 103 6 3 8.1 6 0.6 78 6 4 11.2 6 0.4 109 6 6 5.3 6 0.4 53 6 5
Series 3
Vehicle 5 + cediranib 6 372 6 12 105 6 4 9.1 6 0.7 88 6 6 7.2 6 0.7 69 6 6 4.5 6 0.3 44 6 4
Losartan + cediranib 8 382 6 15 99 6 2 9.5 6 0.6 96 6 6 10.4 6 0.8 104 6 7 5.3 6 0.3 54 6 4
Series 4 baseline values:
Vehicle 6 + cediranib 6 347 6 10 107 6 8 11.2 6 3.0 102 6 20 9.4 6 1.2 90 6 17 5.5 6 0.4 51 6 3
Bosentan + cediranib 4 365 6 8 99 6 3 8.1 6 2.4 80 6 23 10.4 6 1.4 107 6 16 5.8 6 0.9 58 6 8
Phentolamine/propranolol +
cediranib
7 351 6 13 104 6 3 7.4 6 1.2 71 6 12 11.6 6 0.9 111 6 9 6.3 6 0.4 60 6 4
Data show baseline cardiovascular variables. Measurements (means6 SEM) were made immediately before administration of drugs or vehicle
according to 4 experimental series described in Materials and Methods. n, number of animals in each experimental group. Units for VC are kHz ×
mmHg · 1023. RDS, renal Doppler shift; MDS, mesenteric Doppler shift; HDS, hindquarters Doppler shift.
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Series 1: Effects of cediranib and sorafenib
Administration of vehicle caused no consistent cardio-
vascular effects in either group, although there was
some reduction in HR and HVC across the 4-d recording
period (Fig. 1, Friedman’s test). Cediranib at both 3 and
6 mg/kg produced a sustained elevation of MAP over
the 4-d experimental period (Fig. 1, Friedman’s test);
however, neither dose of cediranib produced a consis-
tent change in HR. At both doses, the pressor effect was
accompanied by significant vasoconstrictions in the
mesenteric and hindquarters vascular beds (Fig. 1). At
the lower dose of cediranib (3 mg/kg; 3 mg/kg/h), no
significant change was seen in RVC (Fig. 1A), but at
the higher dose (6 mg/kg; 6 mg/kg/h), there was a
significant renal vasoconstriction (Fig. 1B). These
treatment-induced pressor and vascular effects were
significantly different from the vehicle group over the
4-d experimental period (Mann-Whitney U test, in-
tegrated area under curve, 0–76 h). In cases in which
both Friedman and Mann-Whitney tests were positive,
we conducted an additional Mann-Whitney test be-
tween treated and vehicle groups at each time point
to determine the time of onset of the cardiovascular
effects. For almost all points of analysis, there was a sig-
nificant difference between the 2 groups after 24 h (P ,
0.05, Fig. 1 and Table 2).
Sorafenib at 10 or 20 mg/kg also produced sus-
tained increases in MAP relative to baseline values
(Fig. 2, Friedman’s test). This pressor effect was ac-
companied by significant decreases in HVC, which
were observed at both doses of sorafenib, although
the changes at the higher dose of sorafenib were
less consistent (Fig. 2, Friedman’s test). There was
some mesenteric vasoconstriction (relative to basal;
Freidman’s test), particularly after the higher dose of
sorafenib, but the integrated change was not signifi-
cantly different from vehicle, and there were no
consistent significant changes (with respect to vehicle
controls) in RVC (Mann-Whitney U test, integrated
area under curve, 0–76 h; Fig. 2). No significant
changes in HR were seen at the lowest dose of
sorafenib, but a consistent and significant tachycardia
(relative to vehicle controls) was observed at the
highest dose after 48 h (Mann-Whitney U test, inte-
grated area under curve, 0–76 h, Fig. 2B). The time-
course of the responses to sorafenib are summarized in
Table 2.
Figure 1. Cardiovascular responses to cediranib in conscious, freely moving rats. Rats were dosed with either 3 mg/kg, i.v. (initial
bolus followed by 3 mg/kg/h, i.v. infusion for 1 h; n = 8) (A) or 6 mg/kg, i.v. (initial bolus followed by 6 mg/kg/h, i.v. infusion for
1 h; n = 8) cediranib (B). Vehicle controls (n = 7, A; n = 8, B) were administered 5% propylene glycol, 2% Tween 80 in sterile
saline) as described in Materials and Methods. Data points are means; vertical bars represent SEM. u, signiﬁcant difference
between-group comparison (P , 0.05; Mann-Whitney U test, 0–76 h) based on integrated area under or above curve analysis.
Where both above tests were positive, Mann-Whitney U test was conducted between treated and vehicle control groups at each
timepoint. *P , 0.05 vs. baseline (Friedman’;s test); #P , 0.05 vs. vehicle control (Mann-Whitney U test).
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Series 2: Effects of vandetanib and pazopanib
Administration of vehicle in the control group for
vandetanib caused no consistent cardiovascular effects,
although there was some reduction in HR and HVC
across the 4-d recording period (Fig. 3, Friedman’s test).
Vandetanib (12.5 and 25 mg/kg, i.p.) produced a sus-
tained increase in MAP (Fig. 3, Friedman’s test), which
at the lower dose was accompanied by a significant fall
in HVC only, whereas at the higher dose there was
also a significant fall in MVC (Fig. 3, Friedman’s test).
Comparison of integrated responses over the 76-h
TABLE 2. Changes in cardiovascular variables induced by different RTKI
RTKI Dose (mg/kg)
Change in cardiovascular variable (h) Target RTK and Kd (nM)
a
HR MAP RVC MVC HVC VEGFR2 RET PDGFR-A EGFR KIT
Cediranib Low: 3, i.v. NE 124 NE 224 224 1.1 6.1 0.4 230
High: 6, i.v. NE 124 224 22 23
Sorafenib Low: 10, i.v. NE 13 NE NE 24 59 13 62 35 28
High: 20, i.v. 148 124 NE NE 21
Vandetanib Low: 12.5, i.p. NE 124 NE NE 226 820 34 230 9.5
High: 25, i.p. NE 124 NE 248 224
Pazopanib Low: 30, i.p. NE 124 226 224 NE 14 310 4.9 2.8
High: 100, i.p. NE 124 NE 224 24
Signiﬁcant changes in cardiovascular variables (P , 0.05, Mann-Whitney U test) indicated by between-group comparison (P , 0.05; Mann-
Whitney U test) as indicated by u in Figs. 1–4. Time (h) to earliest signiﬁcant change in this experimental series (P , 0.05; Mann-Whitney U test)
from corresponding time-matched vehicle control is also shown in parentheses (when it is also accompanied by signiﬁcant change from basal
levels). aIn vitro Kd values (nM) (31) reported on isolated proteins for VEGFR2 and other receptor tyrosine kinases. NE, no effect detected.
Figure 2. Cardiovascular responses to sorafenib in conscious, freely moving rats. Rats were dosed with either 10 mg/kg, i.v. (initial
bolus followed by 10 mg/kg/h, i.v. infusion for 1 h; n = 8) (A) or 20 mg/kg, i.v. (initial bolus followed by 20 mg/kg/h, i.v. infusion
for 1 h; n = 7) sorafenib (B). Vehicle controls (n = 7, A; n = 8, B) were administered 5% propylene glycol, 2% Tween 80 in sterile
saline as described in Materials and Methods. These vehicle controls are same as those in corresponding Fig. 1A, B. Data points
are means; vertical bars represent SEM. *P, 0.05 vs. baseline (Friedman’s test; u, signiﬁcant between-group comparison, P, 0.05;
Mann-Whitney U test, 0–76 h) based on integrated area under or above curve analysis. Where both above tests were positive,
Mann-Whitney U test was conducted between treated and vehicle control groups at each timepoint. #P , 0.05.
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experimental period showed that these effects were
significantly different from the vehicle group (Mann-
Whitney U test, integrated area under curve, 0–76 h;
Fig. 3). Differences from vehicle were observed be-
tween 24 and 26 h after the initiation of treatment
(Mann-Whitney U test; Table 2). There were no con-
sistent changes in RVC after either dose of vandetanib
(Fig. 3, Friedman’s test). Moreover, neither dose of
vandetanib caused a consistent change in HR.
Administration of vehicle in the control group for
pazopanib did not evoke any consistent cardiovascular
changes, except in the hindquarters vascular bed,
where some vasoconstriction over the 4-d experimental
period was apparent (Fig. 4, Friedman’s test). Pazopanib
at 10 mg/kg, i.p. produced no consistent changes in
MAP(n=8;datanot shown).However, at both 30mg/kg,
i.p. and 100 mg/kg, i.p., pazopanib evoked sus-
tained increases in MAP, associated with pronounced
mesenteric vasoconstrictions (Fig. 4, Friedman’s test).
At the lower dose, a small but significant reduction in
RVC was observed (Fig. 4A, Friedman’s test), which
was not seen at the higher dose, although that dose
did cause a hindquarters vasoconstriction (Fig. 4B,
Friedman’s test). There were no consistent effects of
pazopanib onHR at either dose (Fig. 4). Between-group
comparison showed that the pressor responses to
pazopanib at both doses were significantly different
from vehicle over the 76-h experimental period. At the
lower dose, the reductions in RVC and MVC were
different from vehicle, whereas at the higher dose, the
pazopanib-induced mesenteric and hindquarters va-
soconstrictions were different from vehicle (Mann-
Whitney U test, integrated area under curve, 0–76 h;
Fig. 4). As with the other compounds, this was gener-
ally seen at and after 24 h (Mann-Whitney U test;
Table 2).
Series 3: Effects of losartan on the
hypertension induced by cediranib
In an attempt to unravel the mechanisms underlying
the hypertension induced by the most potent RTKI,
cediranib, we evaluated the effects of pretreatment
with the AT1R antagonist losartan (28) on the cardio-
vascular responses to cediranib. In this series of ex-
periments, cediranib produced similar effects on MAP
and regional VC (relative to predrug baseline values;
Figure 3. Cardiovascular responses to vandetanib in conscious, freely moving rats. Rats were dosed with either 12.5 mg/kg i.p.
(n = 8) (A) or 25 mg/kg, i.p. (n = 8) vandetanib (B). Vehicle controls (n = 8) were administered 5% propylene glycol, 2%
Tween 80 in sterile saline intraperitoneally, as described in Materials and Methods. These vehicle controls are identical in A
and B. Data points are means; vertical bars represent SEM. *P , 0.05 vs. baseline (Friedman’s test). u, signiﬁcant between-
group comparison (P , 0.05; Mann-Whitney U test, 0–76 h) based on integrated area under or above curve analysis. Where
both above tests were positive, Mann-Whitney U test was conducted between treated and vehicle control groups at each
timepoint. #P , 0.05.
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Friedman’s test) to those seen in earlier experiments
(Fig. 5). The hypertensive and vasoconstrictor effects
of cediranib were not inhibited by treatment with
losartan; indeed, the effects on MAP and MVC were
slightly enhanced (Mann-Whitney U test; Fig. 5).
Series 4: Effects of endothelin-1 receptor
antagonism or a- and b-adrenoceptor
antagonism on responses to cediranib
The effects of antagonism of endothelin-1 receptor (24) or
a- and b-adrenoceptors (29) on cediranib-induced pressor
and regional vasoconstrictor effects were finally evalu-
ated. Treatment with bosentan had no significant effects
on the hemodynamic responses to cediranib compared to
the vehicle group.
At the 48-h timepoint, animals treated with vehicle
and low-dose cediranib showed a reduction in HR of
326 9 beats/min, an increase inMAP of 306 4mmHg,
and reductions in VC in the renal, mesenteric, and
hindquarters vascular beds of 239.8 6 6.9, 244.8 6
5.0, and 258.0 6 4.2%, respectively (n = 6). In the
presence of bosentan, cediranib evoked a rise in MAP
(29 6 4 mmHg) and reductions in RVC, MVC, and
HVC (250.0 6 5.3, 249.8 6 3.8, and 256.3 6 4.9%,
respectively; n = 4), and these changes were not dif-
ferent from those seen in the vehicle and low-dose
cediranib groups. The effect on HR was somewhat
more variable over the experimental time period in the
presence of bosentan, and at 48 h, HR was 212 6 13
beats/min compared to baseline (immediately before
the start of any treatment on d 1).
In the presence of bosentan, cediranib evoked a rise
in MAP (29 6 4 mmHg) and reductions in RVC, MVC,
and HVC (250.06 5.3,249.86 3.8, and256.36 4.9%,
respectively; n = 4). These changes were not different
from those seen in the vehicle and low-dose cediranib
group. The effect on HR was somewhat more variable
over the experimental time period in the presence of
bosentan, and at 48 h, HR was 212 6 13 beats/min
compared to baseline (immediately before the start of
any treatment on d 1).
In the presence of phentolamine and propranolol,
cediranib caused an elevation in MAP (34 6 4
mmHg), which was accompanied by reductions in
RVC, MVC, and HVC (230.7 6 12.9, 262.0 6 2.9,
and 254.8 6 2.7%, respectively; n = 7). At the 48-h
timepoint, there was a variable change in HR (2276
21 beats/min). Compared to the vehicle and low-dose
Figure 4. Cardiovascular responses to pazopanib in conscious, freely moving rats. Rats were dosed with either 30 mg/kg, i.p.
(n = 8) (A) or 100 mg/kg, i.p. (n = 8) pazopanib (B). Vehicle controls (n = 8) were administered 5% propylene glycol, 2% Tween
80 in sterile saline intraperitoneally as described in Materials and Methods. These vehicle controls are identical in A and B. Data
points are means; vertical bars represent SEM. *P , 0.05 vs. baseline (Friedman’s test). u, signiﬁcant between-group comparison
(P , 0.05; Mann-Whitney U test, 0–76 h) based on area under or above curve analysis. Where both above tests were positive,
Mann-Whitney U test was conducted between treated and vehicle control groups at each timepoint. #P , 0.05.
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cediranib group, exposure to adrenergic blockade
caused an enhanced cediranib-induced vasoconstrictor
response in themesenteric vascular bed (Mann-Whitney
U test).
DISCUSSION
In the present study, we, like others (23), have shown
that in conscious rats, hypertension can be induced by
RTKIs, as described in humans (13–17). Furthermore,
we have been able to demonstrate for the first time that
the onset of the hypertension is associated with re-
gionally selective vasoconstrictions. The elevation in
MAP was most consistently associated with a hind-
quarters vasoconstriction, although the mesenteric
vascular bed was also affected. In all cases, RVC was
least affected. Hypertension was observed with 4 dif-
ferent RTKIs that differ markedly in their ability to
bind to VEGFR2 and inhibit functional activity
(Table 2) (27, 31). For example, the most potent in-
hibitor of VEGFR2 used in the present study, cediranib
(Table 2) (27, 31), produced an increase (within 24 h) in
MAP. This was accompanied by consistent vasocon-
strictions in both the hindquarters and mesenteric
vascular beds (Table 2), with a decrease in RVC only
apparent at the higher dose used (Table 2).
The increase in MAP was normally apparent within
24 h for all 4 RTKIs studied. This is rather different from
the slower development of hypertension produced by
antibody-based VEGF inhibitors in humans, particu-
larly the monoclonal antibody bevacizumab, where the
median interval from first dose of treatment to onset of
hypertension ranged from 7–316 d (32). The time course
of the development of hypertension with bevacizumab
suggests that the mechanism of action may involve
persistent changes in gene expression such as sup-
pression of NO synthesis (15, 17, 33) and/or vascular
rarefaction as a result of impaired angiogenesis over a
longer period of time (15, 34–36). A role for NO in the
ability of endogenous VEGF to maintain a low BP has
been also suggested by previous work that showed
that pretreatmentwithN-nitro-L-argininemethyl ester
(L-NAME), an inhibitor of NO synthase, increased BP in
control-treatedmice to the same extent as that observed
in animals treated with an anti-VEGFR2 (37). This ob-
servation, coupled with the finding that VEGFR2
treatment decreased eNOS and iNOS mRNA expres-
sion, suggests that VEGF may act to reduce BP via in-
duction of NO and that VEGF inhibitor-mediated
hypertension may be at least in part due to inhibition of
NO (37).
Rarefaction is a reduction in the density ofmicrovessels
that leads to a decrease in vascular surface area and an
increase in vascular resistance (15). However, it has been
difficult todeterminewhether rarefaction is the causeor an
effect of hypertension (35, 36).
Consistent with the findings presented here, more
recent experimental and clinical studies have demon-
strated RTKI-induced hypertensive effects within hours
to days of treatment (38–41). The significant changes in
MAP seen in the present study after 24 hwith all 4 RTKIs
are consistent with previous suggestions that the pres-
sor effectsmay be due to changes in gene expression (15,
17, 33, 37), although the time course is probably too short
for an involvement of vascular rarefaction (15, 34–36).
Therewere variable effects of the different RTKIs onHR.
We suggest that these inconsistent hemodynamic effects
are likely to be due to their other kinase inhibitor
properties, which are different for the 4 RTKIs studied
(Table 2).
The most striking and original finding in the current
study, however, was the hindquarters vasoconstriction
that was observed over the same time course as the
change in BPwith all 4 RTKIs.As such, this is likely to be
a major contributor to the observed increase in MAP
with these drugs. There was also a tendency for these
effects on HVC to occur earlier at the higher doses of
RTKIs (Table 2). More variable effects were seen in
MVC, with significant differences between the RTKIs
Figure 5. Effect of AT1R antagonist losartan on hypertension
induced by cediranib. Rats were dosed intravenously with
either losartan (10 mg/kg initial bolus, followed by 10 mg/kg/h
continuous infusion; n = 8) or vehicle control (sterile saline;
n = 6) over 5 h. After 1 h, each group was administered
cediranib (3 mg/kg; 3 mg/kg/h infusion, i.v.). Data points are
means; vertical bars represent SEM. *P , 0.05 vs. baseline
(Friedman’s test). u, signiﬁcant between-group comparison
(P , 0.05; Mann-Whitney U test, 0–48 h) based on integrated
area under or above curve analysis. Where both above tests were
positive, Mann-Whitney U test was conducted between treated
and vehicle control groups at each timepoint. #P , 0.05.
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studied. Thus, consistent vasoconstrictions in the mes-
enteric vascular bed were seen with cediranib and
pazopanib, but less so with sorafenib and vandetanib.
These differences are likely to be due to their different
affinities for a range of other tyrosine kinases (27), some
of which are illustrated in Table 2. The effects of all
RTKIs were less consistent in the renal vascular bed,
although at high doses there was some evidence of a
vasoconstrictor effect, particularlywith themore potent
RTKIs, such as cediranib. This may point toward an
autoregulatory role within the kidney (42) that goes
some way toward compensating for the RTKI-induced
reduction in RVC.
Interestingly, the results described herein are
similar to previous reports of regional hemodynamic
changes in rats after chronic NO synthase inhibition
with L-NAME (43), where it was shown that L-NAME
infusion caused an elevation in MAP, together with
significant vasoconstriction in the hindquarters vas-
cular bed. There was also a reduction in MVC, but
little effect on RVC (43). This would be consistent
with a role for NO in the mechanism by which en-
dogenous VEGF is able to contribute to the homeo-
static control of MAP via activation of VEGFR2 and
subsequent calcium mobilization in vascular endothelial
cells. The in vivo regional hemodynamics model de-
veloped here with RTKIs will allow future mecha-
nistic studies to be undertaken to explore this in more
detail.
Previous observations have suggested that the hy-
pertension that develops in humans with bevacizumab
can be managed with standard antihypertensive drugs
(32). For example, there are reports that combinations of
sympathetic blockade, in addition to diuretics, and re-
nin angiotensin system inhibitors may be safe and ef-
ficacious for use in lowering BP in patients treated with
anti-VEGF cancer therapies (44). In order to investigate
whether the hypertension and other cardiovascular ef-
fects associated with RTKIs could also be prevented by
antagonism of the actions of angiotensin II, endothelin-
1, or catecholamines (21), we here investigated the im-
pact of drugs that interfere with the actions of these
signaling pathways.
Losartan treatment did not attenuate the increase
in BP induced by cediranib. Indeed, there was greater
elevation in MAP induced by cediranib in the pres-
ence of this AT1R antagonist. This pressor effect was
accompanied by an increase in the mesenteric vaso-
constriction normally observed with cediranib, al-
though it is likely that losartan itself reduced BP and
caused a slight mesenteric vasodilatation, thereby
contributing to an enhanced change. These effects
were apparent after 24 h. The lack of antagonism by
losartan is consistent with other studies that dem-
onstrated that inhibition of angiotensin II signaling
with an angiotensin-converting enzyme inhibitor,
captopril, was not able to offset the BP-elevating ef-
fects of sunitinib in rats instrumented with radio-
telemetric devices (45). However, it should be
acknowledged that other studies have shown that
when the BP effects of an RTKI are marginal (that is,
an elevation of #10 mmHg), a high dose of captopril
was reported to completely reverse the rise in BP in a
rat model (46).
Previous work with the endothelin-1 receptor an-
tagonist macitentan has suggested that it can attenu-
ate the increase in BP induced by sunitinib (45).
However, in the present study, administration of the
endothelin-1 receptor antagonist bosentan (24) did
not produce any significant attenuation of the in-
crease in MAP induced by cediranib. Similarly, an-
tagonism of both a- and b-adrenoceptors with a
combination of the nonselective a-antagonist phen-
tolamine and the b-blocker propranolol (29) also had
no effect on the increase inMAP induced by cediranib.
There was, however, a noticeable enhancement of the
mesenteric vasoconstrictor actions of cediranib in the
presence of phentolamine and propranolol. The obser-
vation that the reduction in MVC is enhanced during
adrenergic receptor blockade is compatible with the idea
that the rise in BP is associated with a decrease in sym-
pathetic tone counteracting the rise in BP.
It is clear from the foregoing discussion that in-
terference with the actions of endothelin-1, angio-
tensin II, or catecholamines did not prevent the
hypertension or the regionally selective vasoconstric-
tions induced by cediranib. There is therefore no evi-
dence from our nonclinical animal model to suggest
that antihypertensive drugs aimed at the sympathetic
nervous system or hormones acting on endothelial
cells will be effective in the treatment of hypertension
induced by RTKIs. These data point to an urgent need
to understand the mechanisms underlying the specific
effects of RTKIs on regional blood flow, in particular in
vascular beds that lead to a generalized increase in
MAP, and the need to consider new antihypertensive
strategies for patients being treated with these agents.
The regional hemodynamic effects of RTKIs observed
in conscious, freely moving rats in the present study
suggest that this in vivo translational model provides
an exquisitely sensitive and powerful approach with
which to systematically unravel the complexities
involved.
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